Actuate Therapeutics Inc (ACTU) vs Kyntra Bio, Inc. (KYNB)
A side-by-side comparison of Actuate Therapeutics Inc and Kyntra Bio, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ACTU
Actuate Therapeutics Inc
$0.81HealthcareDelayed quote: Oct 6, 2026, 9:59 AM EDT
KYNB
Kyntra Bio, Inc.
$6.14HealthcareDelayed quote: Oct 6, 2026, 9:56 AM EDT
Total return — ACTU vs KYNB
growth of $100 · dividends reinvested · last 2yACTU -89.8% (-68.1%/yr)KYNB -40.5% (-22.8%/yr)KYNB compounded faster over this window
Log scale — wide-divergence pair
ACTU KYNB
ACTU vs KYNB: by the numbers
- •KYNB is the larger company ($25M vs $19M market cap).
- •KYNB is profitable (3967.77% net margin) while ACTU runs a net loss (0.00%).
Metrics side by side
Valuation
| Metric | ACTU | KYNB |
|---|---|---|
| P/S ratio | N/A | 5.38 |
| P/B ratio | 19.47 | N/A |
Profitability
| Metric | ACTU | KYNB |
|---|---|---|
| Gross margin | 0.00% | 91.37% |
| Operating margin | 0.00% | -712.66% |
| Net margin | 0.00% | 3967.77% |
| ROE | -2067.81% | N/A |
| ROIC | -1489.99% | -78.16% |
Growth (annualized)
| Metric | ACTU | KYNB |
|---|---|---|
| Revenue CAGR (5Y) | N/A | -51.49% |
| Total return CAGR (5Y) | N/A | -52.67% |
Frequently asked
- Is ACTU or KYNB more profitable?
- KYNB runs the higher net margin — ACTU at 0.00% versus KYNB at 3967.77%.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.